Basgen Bio (CEO Ho Kim) announced on the 21st that it has been selected as the lead organization for the "2025 Research and Development Special Zone AI Global Big Tech Fostering Project (Competitive R&BD)" hosted by the Ministry of Science and ICT. This project is a large-scale support program aimed at fostering the core artificial intelligence (AI) technologies of promising companies within the R&D Special Zone to a global level.
With this selection, Basgen Bio will receive a total of 4.6 billion won in technology development and commercialization funding over the next three years. Participating organizations include Pohang University of Science and Technology, Yonsei University, Sookmyung Women's University Industry-Academic Cooperation Foundation, HLB Biostep Co., Ltd., and Navion Co., Ltd.
Through this project, Basgen Bio plans to commercialize a clinical trial simulation solution based on Clinical Twin. Clinical Twin is a technology that enables virtual clinical trials by reproducing actual patient clinical data in a digital environment. The goal is to optimize clinical design and pre-verify the likelihood of success.
In this process, Basgen Bio will leverage its own biobank of approximately 156,000 individuals and multi-omics data from 500,000 individuals across multiple ethnicities. With Pohang University of Science and Technology (POSTECH), the company plans to jointly develop molecular clustering AI technology based on drug efficacy correlations and apply it to a clinical simulation platform. This will enhance the accuracy of drug efficacy and toxicity predictions and ensure expanded indications.
Basgen Bio previously participated in the world's largest bio event through the Seoul Bio Hub's "2024 BIO USA" support project. Through this engagement with global pharmaceutical companies, Basgen Bio identified market needs and confirmed overseas demand for its ClinicalTwin technology. The company explained that this project win is an extension of these preliminary exchanges.
Kim Ho, CEO of Basgen Bio, said, “This selection is a comprehensive recognition of our AI-based new drug development technology and commercialization potential,” and added, “We will increase clinical efficiency and success rate through our clinical trial simulation solution based on ClinicalTwin, and grow it into a platform that can be utilized in the global market.”
He added, "We will continue to strengthen our research and development capabilities that integrate AI and clinical data to lead the digital transformation of the global pharmaceutical and bio industries."
- See more related articles
You must be logged in to post a comment.